CR20220631A - Compuestos de dihidroquinolinsulfonamida de ciclobutilo - Google Patents
Compuestos de dihidroquinolinsulfonamida de ciclobutiloInfo
- Publication number
- CR20220631A CR20220631A CR20220631A CR20220631A CR20220631A CR 20220631 A CR20220631 A CR 20220631A CR 20220631 A CR20220631 A CR 20220631A CR 20220631 A CR20220631 A CR 20220631A CR 20220631 A CR20220631 A CR 20220631A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- dihydroquinoline
- cyclobutyl
- sulfonamide compounds
- formula
- Prior art date
Links
- PAPIDPZGJVSNRS-UHFFFAOYSA-N N-cyclobutyl-1,2-dihydroquinoline-2-sulfonamide Chemical class O=S(C1NC2=CC=CC=C2C=C1)(NC1CCC1)=O PAPIDPZGJVSNRS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010011224 Cough Diseases 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- -1 cyclobutyl dihydroquinoline sulfonamide compound Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de dihidroquinolinsulfonamida de ciclobutilo de Fórmula (I), (I); un enantiómero, diastereoisómero, atropisómero del mismo, una mezcla de los mismos o una sal farmacéuticamente aceptable del mismo, que inhibe los canales de sodio activados por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención. También se proporciona además una preparación atropi-selectiva de dichos compuestos de Fórmula (I), y un producto intermedio de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037001P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/036896 WO2021252820A1 (en) | 2020-06-10 | 2021-06-10 | Cyclobutyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220631A true CR20220631A (es) | 2023-01-23 |
Family
ID=76797115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220631A CR20220631A (es) | 2020-06-10 | 2021-06-10 | Compuestos de dihidroquinolinsulfonamida de ciclobutilo |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US12240839B2 (es) |
| EP (2) | EP4653050A3 (es) |
| JP (2) | JP7739051B2 (es) |
| KR (1) | KR20230022996A (es) |
| CN (2) | CN119735588A (es) |
| AR (1) | AR122592A1 (es) |
| AU (1) | AU2021288696A1 (es) |
| BR (1) | BR112022025201A2 (es) |
| CA (1) | CA3183889A1 (es) |
| CL (1) | CL2022003499A1 (es) |
| CO (1) | CO2022017903A2 (es) |
| CR (1) | CR20220631A (es) |
| DK (1) | DK4165024T3 (es) |
| ES (1) | ES3037072T3 (es) |
| FI (1) | FI4165024T3 (es) |
| HR (1) | HRP20251229T1 (es) |
| HU (1) | HUE072945T2 (es) |
| IL (2) | IL298325B1 (es) |
| JO (1) | JOP20220334A1 (es) |
| LT (1) | LT4165024T (es) |
| MA (1) | MA59968B1 (es) |
| MX (2) | MX2022015856A (es) |
| PE (1) | PE20230860A1 (es) |
| PL (1) | PL4165024T3 (es) |
| PT (1) | PT4165024T (es) |
| RS (1) | RS67268B1 (es) |
| SI (1) | SI4165024T1 (es) |
| SM (1) | SMT202500328T1 (es) |
| TW (1) | TWI899251B (es) |
| UY (1) | UY39263A (es) |
| WO (1) | WO2021252820A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| CA3228542A1 (en) * | 2021-08-12 | 2023-02-16 | Tyk Medicines, Inc. | Polycyclic compound and use thereof |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4412994A (en) | 1980-04-24 | 1983-11-01 | Interx Research Corporation | Mannich-base hydroxamic acid prodrugs, compositions and use |
| US5707985A (en) | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
| PA8444901A1 (es) | 1997-01-28 | 2000-05-24 | Hoffmann La Roche | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
| CN1315836C (zh) | 2002-04-26 | 2007-05-16 | 奥索-麦克尼尔药品公司 | 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环 |
| BRPI0406778A (pt) | 2003-01-17 | 2006-01-17 | Warner Lambert Co | Antagonistas de receptores de androgênio |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| DK1879877T3 (da) | 2005-05-03 | 2013-04-15 | Ranbaxy Lab Ltd | Antimikrobielle midler |
| KR20080015102A (ko) | 2005-05-10 | 2008-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| ATE527251T1 (de) | 2005-05-16 | 2011-10-15 | Vertex Pharma | Bicyclische derivate als modulatoren von ionenkanälen |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| US20120189546A1 (en) | 2009-07-11 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Radiolabelling Method Using Cycloalkyl Groups |
| CN102030780B (zh) * | 2010-10-26 | 2014-01-29 | 浙江大学 | 一种手性螺环磷酸和制备方法及其应用 |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| WO2016124140A1 (zh) | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| HK1248687B (en) | 2015-03-02 | 2020-01-10 | Amgen Inc. | Bicyclic ketone sulfonamide compounds |
| CN108602804B (zh) | 2015-12-18 | 2025-05-02 | 美国安进公司 | 烷基二氢喹啉磺酰胺化合物 |
| MX378012B (es) | 2015-12-18 | 2025-03-10 | Amgen Inc | Compuestos de alquinil dihidroquinolina sulfonamida. |
| WO2017165304A2 (en) | 2016-03-21 | 2017-09-28 | The Scripps Research Institute | Pd(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(sp3)-H BOND ACTIVATION |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| CA3228542A1 (en) | 2021-08-12 | 2023-02-16 | Tyk Medicines, Inc. | Polycyclic compound and use thereof |
| WO2023023202A1 (en) | 2021-08-19 | 2023-02-23 | Amgen Inc. | Stereoselective preparation of trans halo cyclobutane |
-
2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 EP EP25188659.4A patent/EP4653050A3/en active Pending
- 2021-06-10 IL IL298325A patent/IL298325B1/en unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/en active Active
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/en not_active Ceased
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 CA CA3183889A patent/CA3183889A1/en active Pending
- 2021-06-10 IL IL326793A patent/IL326793A/en unknown
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 AU AU2021288696A patent/AU2021288696A1/en active Pending
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
-
2022
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
-
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010506A (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| EP4595965A3 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| MX2023001445A (es) | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| MX2024003459A (es) | Metodos de tratamiento de trastornos metabolicos. | |
| MX2023006578A (es) | Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas. | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| ZA202309001B (en) | Abhd6 antagonist | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| MX2025001111A (es) | Nuevas sulfonamidas y su uso como agentes neuroprotectores y/o neurorrestauradores | |
| MX2022008931A (es) | Composiciones farmaceuticas y sus usos. | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| MX2022008930A (es) | Composiciones farmaceuticas y sus usos. | |
| AU2002254124A1 (en) | Aryl-n-cyanoguanidines and methods related thereto | |
| WO2024168106A3 (en) | Modulators of trpml, their compositions and methods of use | |
| MX2024013549A (es) | Heterociclos novedosos, métodos de preparación y usos de los mismos | |
| WO2024050431A3 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases |